Shares of Aurobindo Pharma dropped over 4 percent to ₹1,039 on August 20, 2025, after reports said the company is in talks to acquire Prague-based generic drugmaker Zentiva for $5–5.5 billion (₹43,500–47,900 crore).
Biggest-Ever Pharma Deal by an Indian Firm
If this deal happens, it would be the largest acquisition ever by an Indian pharmaceutical company, both in India and overseas. It would surpass the 2014 Ranbaxy deal, when Daiichi Sankyo sold its stake for $3.2 billion, and also the Biocon Biologics-Viatris transaction worth $3.3 billion.
According to reports, buying Zentiva would help Aurobindo expand its European presence, especially in countries like the Czech Republic, Romania, and Slovakia. These Eastern European markets are expected to grow strongly as patents for big prescription drugs expire, creating opportunities for generics and biosimilars.
Stock Performance and Financials
So far in 2025, Aurobindo Pharma’s stock has fallen 21 percent, while the benchmark Nifty 50 index has gained 2 percent. Investors remain cautious about the company’s performance despite steady business growth in Europe.
In its latest financial results for Q1 FY26 (April–June 2025), Aurobindo posted a net profit of ₹824 crore, down 10.2 percent year-on-year from ₹918 crore in Q1 FY25. Revenue, however, increased 4 percent to ₹7,868 crore from ₹7,567 crore last year.
Operating EBITDA stood at ₹1,603 crore, nearly flat compared with ₹1,619.6 crore a year earlier. The EBITDA margin slipped to 20.4 percent from 21.4 percent.
The company’s US formulations revenue fell 1.9 percent to ₹3,488 crore ($408 million) due to destocking and seasonal factors. On the other hand, its European formulations business grew 18 percent, reaching ₹2,338 crore, showing strong momentum in that region.
Looking Ahead
The Zentiva acquisition, if finalized, could mark a major turning point for Aurobindo Pharma by giving it scale, market access, and growth potential in Europe. However, the share price reaction shows that investors are weighing the risks of such a large deal along with its long-term benefits.
